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Abstract
Replication-competent oncolytic adenoviruses hold
considerable promise for treating malignant gliomas.
The toxicity of the clinically tested E1B-55 kDa mutant
virus is negligible; however, its full clinical potential is
still being evaluated. The purpose of the present study
is to compare the antiglioma activity in vitro and in vivo
between Delta-24, an E1A mutant adenovirus, and
RA55, an E1B-55 kDa mutant adenovirus. We selected
human glioma cell lines that were tumorigenic in nude
mice and express wild-type p53 (U-87 MG, D54 MG) or
mutant p53 (U-251 MG, U-373 MG) protein. Our studies
demonstrated that Delta-24 induced a more potent anti-
glioma effect in vitro than RA55. Moreover, Delta-24
replicated markedly more efficiently than RA55 in both
wild-type and mutant-p53 scenarios. Importantly, di-
rect intratumoral injection of Delta-24, but not RA55,
significantly suppresses tumor growth in intracranial
(U-87 MG, U-251 MG) or subcutaneous (D54 MG) ani-
mal models. Staining for hexon protein detected
replicating adenoviruses in xenografts infected with
Delta-24, but not with RA55. Collectively, these data
indicate that E1A mutant adenoviruses targeting the
Rb pathway are more powerful putative agents for
antiglioma therapy than E1B mutant adenoviruses,
and suggest that E1A mutant adenoviruses should
be tested in the clinical setting for patients with malig-
nant gliomas.
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Introduction
Glioblastoma is the most common and most malignant
form of glioma. These tumors are locally invasive and
diffusely infiltrating, thus precluding complete surgical
removal. Malignant gliomas are also notoriously resistant
to chemotherapy and radiotherapy [1]. For these reasons, it
is imperative to design novel strategies, capitalizing on
genetic anomalies of brain tumors to develop more
rational and efficacious therapies. Two of the best-studied
abnormalities of glioblastomas involve the regulation of Rb
and p53 proteins. The Rb pathway is abnormal in most
malignant gliomas [1]. However, p53 mutation is only found
in a subset of malignant gliomas—secondary glioblastoma
[2]. Although mutations of the p53 gene are found in only a
minority of these tumors (< 50%), other players in the p53
pathway, including mdm2 and p14ARF, are abnormal in
wild-type p53 tumors as well [1,2]. Replication-competent
adenoviruses have been designed to take advantage of
fundamental genetic defects of cancer cells to preferentially
replicate in and kill cancer cells [3,4]. Although the results
have not been published yet, oncolytic adenoviruses target-
ing p53 have recently been investigated for their suitability
in the treatment of glioma in phase I clinical trials. Adeno-
viruses targeting Rb are second-generation agents that are
currently being examined in preclinical studies [5].
The dl1520 adenovirus is the first replication-competent
adenovirus developed as an anticancer tool [6]. The genome
of this mutant adenovirus encompasses a 827-bp deletion in its
E1B region and a point mutation that generates a stop codon,
which prevents the expression of p53-binding E1B-55 kDa
protein [7]. The underlying theory and characterization of
dl1520 opened up a new field of gene therapy for cancer. It
was initially claimed that the dl1520 adenovirus demonstrated
preferential replication as well as antitumoral efficacy in some
p53-deficient human tumor cells [6,8]. However, in human
malignant glioma xenografts, dl1520 produced cell lysis and
antitumor activity independently of p53 status [9], which could
be explained if dl1520 targets the p53 pathway rather than the
p53 protein [10]. Phase I and phase II clinical trials showed that
dl1520 was well tolerated at the highest practical doses [11].
Unfortunately, when used as single-agent antitumor treatment,
dl1520 did not induce a dramatic anticancer effect in most of
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the treated patients [11,12]. Apparently, efficacy rather than
toxicity is the primary limitation of this virus, so that improve-
ments in the oncolytic potency of newer constructs will be
required to generate an optimal therapeutic effect.
We previously reported on the anticancer effect of
Delta-24, an E1A mutant oncolytic adenovirus [13] whose
adenoviral genome encompasses a deletion of 24 bp en-
coding for the Rb-binding region of the E1A protein (amino
acids 122–129). With this genetic modification, Delta-24
lost the capability to acquire an efficient replication pheno-
type in quiescent normal cells, but its ability to replicate in
cancer cells, whose cell cycles are dysregulated, is not
impaired [13]. The differential pattern of replication in
normal versus cancer cells suggests that Delta-24 selec-
tively induces lytic activity in glioma cells while sparing
postmitotic quiescent normal brain cells. Studies from our
laboratory and others have demonstrated the anticancer
effect of Delta-24 in vitro and in vivo [5,13–17].
This is the first study that compares the antiglioma
efficacy of Delta-24 and an E1B-55 kDa mutant adenovirus
RA55, which is functionally similar to dl1520. Our data
demonstrate that Delta-24 induces a more potent antiglioma
effect than RA55. Thus, in vitro studies of cell viability and
viral replication show that Delta-24 replicates and induces
cytopathic effect (CPE) in glioma cell lines with higher
efficiency than RA55. Moreover, in a series of in vivo experi-
ments, we showed that Delta-24 induces more efficacious
antiglioma activity than RA55.
Materials and Methods
Cell Lines and Adenoviruses
The U-87 MG (expressing wild-type p53), U-373 MG, and
U-251 MG (both expressing mutant p53) [18] human glioma
cell lines were purchased from the American Type Culture
Collection (Rockville, MD). D54 MG cells (expressing wild-
type p53) were generously provided by Dr. Darell Bigner
(Duke University, Durham, NC) [18]. The cells were cultured
in DMEM/F12 supplemented with 10% FBS (Hyclone Labo-
ratories, Inc., Logan, UT), 100 mg/ml penicillin, and 100 mg/ml
streptomycin (Invitrogen, Carlsbad, CA). 293 cells were ob-
tained from Qbiogene, Inc. (Carlbad, CA), which were main-
tained in DMEM supplemented with 10% FBS, 100 mg/ml
penicillin, and 100 mg/ml streptomycin. The cells were cul-
tured at 37jC in a humidified atmosphere of 5% CO2.
The E1B-55 kDa deletion in the RA55 virus was accom-
plished by deleting a fragment ranging from the Sau3AI re-
striction site to the BglII restriction site (2426–3328 bp,
both included) in pXC1 (Microbix Biosystems, Inc., Ontario,
Canada), resulting in pXC1-RA55. This deletion eliminates
the E1B p53-binding domain [19], sparing the E1B-19K re-
gion. The pXC1-RA55 shuttle vector was cotransfected with
pBHG10 (Microbix Biosystems, Inc.) into 293 cells to gen-
erate theRA55 construct through homologous recombination.
The construction of Delta-24 has been previously de-
scribed [13,20]. As controls, we used the wild-type adeno-
virus Ad300 [20], viruses inactivated by exposure to seven
cycles of 125J UV light in a GS Gene Linker UV Chamber
fromBioRad (Hercules, CA), andmock infections with culture
medium. The viruses were grown in 293 cells and purified
by CsCl gradient centrifugation, as previously described [21].
Polymerase Chain Reaction (PCR)
The E1B deletion was confirmed by PCR using sense
(5V- GAATGAATGTTGTACAGGTGGCT-3V) and antisense
(5V-AGGAAAACCGTACC GCTAAAATTG-3V) primers to
amplify a 536-bp region of the wild-type E1B gene. Thirty-
five thermal cycles were performed using the following
conditions: 94jC for 30 seconds, 50jC for 30 seconds,
72jC for 1 minute. Samples were analyzed using 1%
agarose (Sigma, St. Louis, MO) gel electrophoresis.
Cell Viability Assays
The cells used for crystal violet assays were seeded in
six-well plates at 5 104 cells/well and infected 24 hours
later with adenoviruses at the desired multiplicity of infection
(MOI). We concluded the experiment when an MOI of 10 of
one of the viruses produced more than a 75% CPE com-
pared to mock or UV-inactivated viral treatment. The cells
were then stained with 0.1% crystal violet in 20% methanol.
Briefly, the medium was removed, and the cells were fixed
and stained by the crystal violet solution for 3 minutes. After
staining, the crystal violet solution was removed, and the
cells were rinsed with water and then air-dried.
In vitro cytotoxicity was quantified using an MTT (Sigma)
assay to measure cell viability. For this assay, 2 103 cells/
well were seeded in 96-well plates and infected 24 hours
later with 0, 4, 8, or 16 MOI of Delta-24 or RA55, or 16 MOI of
UV-inactivated viruses, or cells were mock-infected. Eight
wells were used for each condition. A total of eight wells was
seeded with untreated glioma cells as a viability control, and
eight wells containing only complete medium were used as a
control for a nonspecific dye reduction. Medium was re-
moved 6 days after treatment, and 100 ml/well MTT solution
(2 mg/ml in DMEM/F12 medium) was added to each well.
The plates were incubated for an additional 4 hours. After
removing the medium, 200 ml of 10% sodium dodecyl sulfate
(SDS) was added to each well. The plates were incubated for
an additional 24 hours and then read on a microplate reader
at a test wavelength of 570 nm.
Viral Replication Assays
Human glioma cells were seeded at 5 104 cells/well in
six-well plates and, 24 hours later, infected with Delta-24,
RA55, wild-type adenovirus Ad300, or UV-inactivated Ad300
at an MOI of 10. After 48 hours of infection, the cells were
scraped into 2 ml of culture medium and lysed with three
cycles of freezing (dry ice–ethanol bath) and thawing (37jC
water bath). The TCID50 method was used to determine the
final viral titration. Briefly, the cell lysates were clarified by
centrifugation and the supernatants were serially diluted in
medium to infect 293 cells in 96-well plates. The cells were
analyzed for CPE 10 days after infection. Final titers were
determined as plaque-forming units (pfu) according to the
validation method developed by Qbiogene, Inc.
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Immunoblotting
Glioma cells were collected and resuspended in PBS
plus protease inhibitor cocktail (Sigma) and then lysed
by adding an equal volume of 2SDS loading buffer. After-
ward, the lysates were heated at 95jC for 10 minutes. Equal
amounts of proteins from the lysates were separated by
SDS polyacrylamide gel electrophoresis (PAGE) and probed
with the following antibodies: adenovirus 5 E1B-55K
(Oncogene, Cambridge, MA), E1B-19K (Ab-1; Oncogene),
viral fiber protein (4D2; NeoMarkers, Inc., Fremont, CA),
adenovirus 2 E1A (13 S-5), and b-actin (Santa Cruz Biotech-
nology, Santa Cruz, CA). The secondary antibodies were
horseradish peroxidase–conjugated antigoat, antirat, or
antimouse IgG antibodies (Santa Cruz Biotechnology).
Finally, the protein bands were visualized using an ECL
Western Blotting Detection System (Amersham Pharmacia
Bioechnology, Piscataway, NJ). Protein expression was
quantified by densitometric analysis with the Scion Image
Beta 4.02 Win computer software (available at http://
www.scioncorp.com/frames/fr_scion_products.htm).
Animal Studies
For the intracranial glioma model, 5105 cells of human
glioma U-87 MG or U-251 MG cells were engrafted into the
caudate nucleus of athymicmice, using a guide screw system
as previously described [22]. Animals with U-87 MG–derived
xenografted tumors were treated with virus on days 3, 5, and
8 after implantation of tumor cells. Animals with U-251 MG
xenografts were treated with a single dose of virus on day 3
postimplantation of tumor cells. The animals were treated
with intratumoral injections of 5 ml of one of the following:
Delta-24, RA55, or UV-inactivated adenovirus. A dose of
1.5 108 pfu was used for each viral injection. Animals
displaying general or localized symptoms of toxicity were
sacrificed. The surviving animals were euthanized at 170 or
63 days after being engrafted with U-87 MG or U-251 MG
human glioma cells, respectively. The removed brains were
fixed in formaldehyde for 24 hours and embedded in paraffin.
Hematoxylin- and eosin-stained slides were evaluated for the
presence of tumor and viral nuclear inclusions.
For the subcutaneous glioma model, 107 D-54 MG cells
were inoculated subcutaneously into the right flanks of 6- to
8-week–old athymic mice. When tumors reached at least
5mm in diameter, they were injected with 109 pfu ofDelta-24,
RA55, or UV-inactivated adenovirus, every 5 to 7 days, a
total of four times. Mice were euthanized when tumors
reached the maximum acceptable size. The animal studies
were carried out in the veterinary facilities of the University of
Texas M. D. Anderson Cancer Center in accordance with
institutional guidelines.
Immunohistochemistry
The presence of adenoviral hexon proteins in the treated
xenografts was assessed by immunohistochemistry. Paraffin-
embedded sections from mouse tumors were deparaffinized
and rehydrated through xylene and ethanol in PBS. Endoge-
nous peroxidase activity was quenched by incubation for
30 min in a solution of 0.3%H2O2 in methanol. Sections were
probed with goat antihexon (Chemicon, Inc., Temecula, CA).
Immunohistochemical staining was performed with Vector
Laboratories ABC kits according to the manufacturer’s
instructions (Amersham Biosciences).
Statistical Analyses
For the in vitro experiments and the analysis of anticancer
effect of the different constructs in the subcutaneous animal
model, we performed two-tailed Student’s t test. Data are
represented as mean ± SD. The in vivo anticancer effect of
different treatments in the intracranial animal model was
assessed by plotting survival curves according to the
Kaplan-Meier method, and groups were compared using
the log-rank test.
Results
The E1A Mutant Delta-24 and the E1B-55 kDa Mutant
RA55 Adenoviruses
Previously, we reported on the generation and characteri-
zation of a tumor-selective adenovirus,Delta-24, which has a
24-bp deletion in the E1A region that encodes the Rb protein-
binding site [13]. Immunoprecipitation analyses verified that
with this deletion,Delta-24was unable to bind the Rb protein.
Viral titration experiments in 293 cells demonstrated that the
Delta-24 adenovirus could replicate in and lyse cancer cells
with great efficiency [13]. To construct RA55, we modified
the genome of wild-type adenovirus by deleting a 903-bp
region in the E1B gene (Figure 1A), which abrogated the
p53-binding region of the E1B-55 kDa protein [19]. We
confirmed the deletion by PCR amplification of the E1B gene
using a downstream primer complementary to the sequence
within the deleted region. The resulting 536-bp PCR frag-
ment could not be amplified from the RA55 genome, al-
though it was present when wild-type or Delta-24 genome
was used as a template (Figure 1B). Sequencing the modi-
fied E1B region confirmed the deletion (data not shown). We
next examined the ability of RA55 to express the wild-type
E1B-55 kDa protein, but immunoblotting assays showed that
RA55-infected cells did not express E1B-55 kDa protein
(Figure 1C), and that the expression of E1B-19 kDa protein
was not affected by the deletion (Figure 1C). Therefore, the
deletion in the RA55 adenovirus results in the abolition of the
wild-type E1B-55 kDa protein maintaining an intact E1B-19
kDa protein, rendering RA55 functionally similar to other
E1B-55 kDa mutant adenoviruses such as d11520.
Delta-24 and RA55 Induced Antiglioma Effect In Vitro
To compare the antiglioma effect of Delta-24 and RA55,
we selected the U-87 MG and D54 MG glioma cell lines,
which express wild-type p53 protein [18], and U-251 MG and
U-373 MG glioma cell lines, which express mutant p53
protein [18]. For cell viability assays, we infected cell cultures
with both viruses as single agent. Crystal violet assessment
of cell death revealed that Delta-24 induced a CPE greater
than 80% in U-87 MG cells at a dose of 5 MOI, 15 days after
infection. At that time point,RA55-mediated anticancer effect
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was 10-fold less potent. Similarly, Delta-24 treatment of
D54 MG cultures produced, 7 days after infection, a 10-fold
increase in cell lysis compared to RA55. When the oncolytic
constructs were tested on U-251 MG or U-373 MG cell lines
(7 and 8 days after infection, respectively), Delta-24 pro-
duced a CPE greater than 90% at a dose of 10 MOI. In these
cell lines, Delta-24 was five-fold more potent than RA55 in
inducing cell lysis. Overall, the anticancer effect of Delta-24
was greater than RA55. This effect was most evident in the
wild-type p53 cell lines (Figure 2A).
To quantify the CPE, we performed MTT analyses of cell
viability, which showed that the dose required to induce a
50% decrease in cell viability (IC50) was significantly lower in
cells infected with Delta-24 adenovirus. In U-87 MG cell
cultures, the IC50 of Delta-24 and RA55 was approximately
3 and 16 MOI, respectively (Figure 2B), whereas the IC50 of
Delta-24 and RA55 in U-251 MG cell cultures was approxi-
mately 2 and 7 MOI, respectively (Figure 2B).
Therefore, we conclude that although both mutant adeno-
viruses induce cell lysis, Delta-24 displays a significantly
more powerful antiglioma effect in vitro than RA55.
Delta-24 Replicated with Higher Efficiency Than RA55
in Glioma Cells
Because Delta-24 and RA55 are both replication-
competent adenoviruses, we wanted to determine if they
were each able to acquire a replication phenotype in human
glioma cells. Using a TCID50 method to titer the production of
new viral progeny, we observed thatDelta-24 replicated by at
least two orders of magnitude more efficiently than RA55 in
both U-87 MG and U-251 MG cells (P < .001, in the two cell
lines, t-test, double-sided) (Figure 3). Importantly, the RA55
titers obtained from the glioma cultures were inferior to the
inoculum dose (5 105 pfu), showing that RA55 replicated
with suboptimal efficiency. These results are consistent with
observations of the poor replication of another mutant E1B-
55K adenovirus, dl1520, in U-87 MG cells. Bischoff et al. [6]
and Kirn [11] reported that dl1520 was unable to replicate
in vitro and in vivo in U-87 MG cells. These data hold promise
for the use of Delta-24 as an oncolytic agent in tumors that
are resistant to the oncolytic effect of dl1520. An important
caveat of these findings is that the difference between these
two viruses in replication was greater in cells with wild-type
p53 than in those with mutant p53. Our data corroborate
previous studies showing that E1B-55 kDa mutant adeno-
viruses replicate with more efficiency in p53-mutant than in
p53–wild-type cancer cells [6,11]. Confirming the fact that
modifying the genome attenuated viral production, both
mutant viruses replicated less efficiently in both glioma
cultures than wild-type adenovirus (Figure 3). The differ-
ences in the ability of all three adenoviruses to replicate
in the two glioma cell lines are probably explained by
the differential expression of the CAR adenoviral receptor in
U-87 MG (low expression) and U-251 MG (high expression)
cell lines [5].
RA55-Infected Cells Showed Abnormal Expression of
E1A and Fiber Proteins
Previous studies examining E1B-mediated regulation of
E1A show that E1A is expressed at higher levels in the
absence of E1B [23,24]. Furthermore, E1B-55 kDa report-
edly promotes the exportation of viral mRNA, but inhibits
the exportation of most cellular mRNA species [25]. These
findings suggest that deleting E1B-55 kDa will result in a
reduced level of viral replication due to the expression of a
disproportionately high level of E1A (due to the lack of the
E1B-mediated suppressive effect on E1A expression) and
a low level of other viral proteins (due to poor nuclear
mRNA export). In this work, we intended to determine if
these factors impaired the replication phenotype of RA55.
Examination of the expression of early and late viral genes
in the cells infected with RA55, Delta-24, or wild-type
adenoviruses revealed that, 24 hours after infection, the
level of E1A protein was very similar in cells infected with
wild-type and Delta-24 adenoviruses (Figure 4). Interest-
ingly, cells infected with RA55 consistently had higher
Figure 1. The RA55 adenovirus. (A) Shown are nonscaled schematic
representations of the genomes of wild-type adenovirus Ad300, Delta-24, and
RA55. The nucleotides deleted in the E1A and E1B sequences are indicated.
E1A, solid box; E1B, hatched box. (B) PCR amplification of E1B confirmed
the deletion in the RA55 adenovirus. The antisense primer was comple-
mentary to the deleted sequence of E1B as described in Materials and
Methods section. A fragment of the expected size of 536 nucleotides was
amplified from the genome of Ad300 and Delta-24 adenoviruses, but no
amplification was detected when RA55 was used as template. PCR products
were analyzed in a 1% agarose gel. M, 1-kb ladder. (C) Immunoblot docu-
menting the expression of E1B proteins in cells infected with RA55. Equal
amounts of protein from the virus-treated cells were separated on a 10%
SDS-PAGE gel. E1B-55 kDa and E1B-19 kDa were detected with specific
antibodies with -actin (42 kDa) expression as a loading control. UVi, UV-
inactivated wild-type adenovirus.
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Figure 2. Antiglioma effect of Delta-24 and RA55 adenovirus in vitro. (A) Crystal violet assessment of cell viability. Monolayers of human glioma cells were
infected at the MOI indicated with RA55 or Delta-24. Viable cells were stained with crystal violet when 10 MOI of Delta-24 produced more than 75% of the
CPE. (B) MTT colorimetric analysis of cell viability. Cells were infected at different MOI of 0–16 pfu/cell of Delta-24 or RA55, or with 16 MOI of UV-inactivated
wild-type adenovirus. Cell viability was measured by MTT assay 6 days after infection. Data are mean ± SD of eight determinations, and are represented as cell
viability relative to UV-inactivated adenovirus-treated cells (equal to 100%). Note that RA55 induces a more powerful antiglioma effect in U-251 MG than in U-87
MG cells.
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levels of E1A protein (Figure 4). In addition, we found high
levels of adenoviral fiber protein, a structural gene
expressed at the late stage of viral replication, in cells
infected with either wild-type or Delta-24, whereas the
expression of fiber protein was barely detectable in RA55-
infected cells (Figure 4). These findings demonstrate an
abnormal level of expression of adenoviral genes in the
E1B-55 kDa mutant adenovirus and are consistent with the
requirement for wild-type E1B protein to produce efficient
adenoviral replication [25]. These data also indicate that, in
addition to impairing the ability of the virus to disable p53,
deleting E1B-55 kDa alters normal viral gene expression,
thus possibly contributing to diminishing viral replication in
infected glioma cells.
Antiglioma Efficacy of Delta-24 and RA55 In Vivo
Finally, we examined the antiglioma effect ofDelta-24 and
RA55 adenoviruses in two intracranial glioma mouse models
and one subcutaneous glioma mouse model. In the intra-
cranial experiments, we injected U-87 MG or U-251 MG cells
into the right basal ganglia of athymic mice through a guide
screw implanted in the mouse skull. This screw-guided
surgical model allowed repeated intratumoral injection of
the viruses [22], a technique that greatly improved the
reproducibility of the procedure. In the U-87 MG glioma
model (with low CAR expression and containing wild-type
p53 protein), the mice were injected with three doses of
viruses on days 3, 5, and 8 after intracranial implantation of
glioma cells. Treatment with Delta-24 largely improved sur-
vival compared to control-treated and RA55-treated groups
(Figure 5A; n = 6, P < .001). Importantly, 50% of the Delta-
24–treated mice, but none of the mice included in the other
two groups, was tumor-free before being selectively eutha-
nized on day 170 (Figure 5A). However, the survival of
glioma-bearing mice treated with RA55 was not markedly
improved compared to control animals treated with an in-
activated adenovirus (Figure 5A; n = 6, P = .2).
We next tested the efficacy of RA55 and Delta-24 in the
U-251 MG xenograft animal model. In this model, we
injected U-251 MG glioma (expressing high levels of CAR
and a mutant p53 protein) with a single dose of each virus on
day 3 after intracranial implantation of glioma cells. We
observed that Delta-24 significantly improved the survival
of the glioma-bearing mice compared to the control group
(Figure 5B; n = 6, P < .05). Conversely, mice treated with
RA55 did not demonstrate significantly improved survival
compared with the controls (Figure 5B; n = 6, P = .22). Im-
portantly, 50% of the Delta-24–treated mice survived with no
symptoms until they were selectively euthanized on day 63
postimplantation (Figure 5B). One of the mice in the group
treated with RA55 survived without showing any symptoms
for more than 60 days (Figure 5B).
To further evaluate the anticancer effect of the mutant
E1A and E1B-55 kDa in vivo, we produced D54 MG–derived
(high CAR/wild-type p53) subcutaneous tumors in nude
mice. Tumors were treated with Delta-24, RA55, or UV-
inactivated adenovirus (n = 6, per group) at a dose of
109 pfu, every 5 to 7 days, for a total of four doses. Delta-24
Figure 3. Replication efficiency of Delta-24 and RA55 in human glioma cell
lines. Forty-eight hours after infection with Ad300, Delta-24, or RA55 at 10
MOI, the viral titers were determined using a TCID50 procedure in 293 cells
as described in Materials and Methods section. Viral titer is expressed as
logarithmic scale of pfu per milliliter (mean ± SD). Both mutant viruses caused
attenuated replication phenotypes compared to wild-type adenovirus. Of
importance, Delta-24 replicated significantly better than RA55 in both glioma
cell lines. *P < .001, t-test, double-sided; +P < .001, t-test, double-sided.
Figure 4. Expression of adenoviral E1A and fiber proteins. (A) Cell lysates
from Ad300, Delta-24, and RA55 at a dose of 50 MOI, or mock-infected U-251
MGcells were collected 24 hours after infection. Equal amount of proteins were
separated on a 10% SDS-PAGE gel. E1A (35–46 kDa) and fiber protein
(62 kDa) were detected with specific antibodies. -Actin is shown as a loading
control. Note that in contrast to lysates from wild-type adenovirus (Ad300) or
Delta-24– infected cells, analyses of lysates fromRA55-infected cells revealed
a higher expression of E1A protein, whereas fiber protein was almost
undetectable. (B) A quantitative representation of the expression of proteins.
The amounts of E1A and fiber protein were quantified with densitometric
analysis and normalized with the corresponding -actin level. The relative
protein level of E1A or fiber expressed by Ad300 is equal to 100%.
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produced an inhibition in the tumor growth of > 70% within
19 days after cell implantation, and > 85% at the end of
the experiment, relative to those tumors treated with UV-
inactivated adenovirus (P < .02). The effect of RA55
treatment on tumor growth was not significant compared
to the control-treated tumors (P > 0.2) (Figure 5C).
To detect adenoviral replication in vivo, we examined
sections of brains where tumor tissue remained. Examina-
tion of hematoxylin and eosin–stained sections revealed a
greater number of inclusion bodies, compatible with adeno-
viral infection and replication, in Delta-24–treated U-87 MG
tumor cells than in RA55-treated cells (data not shown). In
addition, immunohistochemical staining of tumor speci-
mens showed that the expression of hexon protein, a late
structural protein (and indicator of adenoviral replication),
was scattered throughout the tumor in the Delta-24–treated
glioma xenografts (Figure 6A) and a paucity of hexon-
positive cells in RA55-treated tumors (Figure 6B). These
data further confirmed the fact that Delta-24 replicated
with greater efficiency than RA55 in vivo in U-87 MG glioma
cells. Taken collectively, our data confirm the minimal ability
of E1B-55 kDa mutants to replicate in cells with wild-
type p53, and suggest that the Delta-24 adenovirus target-
ing the Rb pathway and expressing an intact E1B protein
could be successfully used in tumors that are resistant
to the anticancer effect of first-generation E1B mutant
oncolytic viruses.
Discussion
In this study, we examined and compared the antiglioma
activities of the E1A mutant Delta-24 adenovirus with the
E1B-55 kDa mutant RA55 adenovirus in in vitro and in vivo
settings. Our data showed that Delta-24 replicated more
efficiently than RA55 in, and accordingly induced, a greater
CPE in a panel of glioma cell lines. Delta-24 was an effec-
tive agent as antiglioma treatment in vivo in glioma cul-
tures expressing wild-type or mutant p53. Treatment with
RA55 resulted in an antiglioma effect, albeit not statisti-
cally significant, in mice bearing xenografts expressing
mutant p53 protein. In human glioma xenografts expressing
wild-type p53, the effect was similar to an inactive adenoviral
control. Analyses of virus-treated tumor sections showed that
Delta-24 replicated efficiently in glioma xenografts. In con-
trast, the replication of RA55 was hardly detectable, strongly
suggesting that suboptimal replication ofRA55 in vivo caused
the reduced anticancer effect.
Our data are consistent with previous observations that
E1B-55 kDa mutants such as dl1520, which are function-
ally similar to RA55, do not acquire a replication phenotype
and do not induce an antiglioma effect in vitro or in vivo in
a U-87 MG glioma cell line [6]. In addition, we observed
that RA55 replicated with a higher efficiency in the mutant
p53 cell line, U-251 MG. These results corroborate the
tenet that E1B-55 kDa mutants target the p53 pathway and
are best able to replicate in cells that express mutant p53
protein or that have an inactive p53 pathway [6].
Although the validity of the above results should, of
course, be limited to the glioma cell lines tested here and
to the particular mutant viruses used in the study, our results
suggest that E1A mutant adenoviruses that target the Rb
pathway aremore potent anticancer agents than E1B-55 kDa
mutants. These results are in agreement with previous
reports in other cancers [26,27]. Our study is the first in vivo
comparison between E1B-55 kDa and E1A mutant oncolytic
adenoviruses in both intracranial and subcutaneous models
of glioma. Our data suggest that tumors that are resistant to
the oncolytic effect of E1B-55 kDa mutant adenoviruses
might instead be sensitive to the effect of E1A mutant
Figure 5. Anticancer effect in vivo. (A and B) Data are represented as a
Kaplan-Meier survival curve from the day of U-87 MG (A) or U-251 MG (B)
intracranial implantation, followed by intratumoral injection with RA55, Delta-
24, or UV-inactivated adenovirus (UVi). The P values (determined by log-rank
test) show significant differences in survival between Delta-24 (P < .05), but
not RA55, and control-treated animals in those glioma animal models. (C)
Representation of the growth of D54 MG-derived tumors implanted
subcutaneously and treated with the indicated constructs. The largest (a)
and smallest (b) diameters of each tumor were measured, and tumor volume
was calculated using the formula: ab2  0.4 [31]. The P values (determined
by two-tailed Student’s t test) show significant differences in tumor volume
between Delta-24– treated tumors, but not RA55, and control-treated tumors
(P < .02).
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adenoviruses. This concept, if proven true, could have
clinical relevance for patients who have been unsuccessfully
treated with dl1520. Although the results of a phase I open
label dose escalation trial with the E1B-attenuated adeno-
virus, dl1520, for patients with recurrent malignant brain
tumors who are undergoing surgical resection are still pend-
ing for publication, early reports have suggested that when
dl1520 is used as a single agent for treating some cancers,
no dramatic antitumor effect has been produced [11]. The
effect of dl1520 was, however, reported to be more benefi-
cial when it was combined with chemotherapy [28]. Thus,
further preclinical studies are needed to exploit a more
effective oncolytic adenoviral therapy for gliomas. Interest-
ingly, Delta-24 with the RGD motif in the fiber protein shows
enhanced antiglioma activity [5,29]. Moreover, and of clinical
relevance, it has been elegantly demonstrated that the
antiglioma effect of Delta-24 RGD is further potentiated by
radiotherapy [29].
Adenoviruses have evolved as a perfect adaptable ge-
nome in which the interrelation between different adenoviral
proteins is critical for their efficient replication. One of the
main principles used in developing an oncolytic virus is to
carefully manipulate the adenoviral genome to eliminate the
ability of the virus to activate normal host cells to enter into
the S-phase or to block altruistic apoptosis in normal cells,
while promulgating a relatively unscathed capacity for viral
replication in cancer cells, thereby improving selectivity
without sacrificing efficacy. This theory suggests that, to
maintain therapeutic potency, oncolytic adenoviruses need
to be generated by introducing only minor changes in the
adenoviral genome to keep as many of the normal adenoviral
protein functions as intact as possible. Accordingly, the
Delta-24 genome encompasses a deletion of only 24 nucle-
otides in the E1A region. This small deletion is, however,
sufficient to prevent binding to and inactivation of the Rb
protein, but it has little effect on the functions of the E1A
protein that are necessary for effective viral replication in
cancer cells [13]. In contrast, the deletion in E1B-55 kDa
mutant adenoviruses is larger and eliminates almost all of the
functions of the E1B-55 kDa protein. Thus, the deletion in
RA55 not only prevents the binding to and inactivation of p53
by E1B-55 kDa protein, but also eliminates other functions
such as downmodulating E1A protein, promoting viral mRNA
transport, and suppressing host cellular protein synthesis
[24,25]. All of these E1B functions are key components of the
adenoviral replication cycle. One of the direct consequences
of the E1B-55 kDa deletion is that E1A is overexpressed. The
subsequent induction of E1A-mediated apoptosis results in
suboptimal adenoviral replication [30]. These observations
suggest that E1B-55 kDa mutant adenoviruses whose muta-
tions are limited to the region responsible for interacting with
p53, but whose other critical functions are preserved, might
be more efficacious in acquiring a replication phenotype in
p53 mutant cancer cells than adenoviruses with a total
abrogation of E1B-55 kDa protein. In reality, the mutation
of a single amino acid is enough to generate an E1B-55 kDa
mutant that is unable to bind to and inactivate p53 [19].
Further experiments are required to test the anticancer effect
of these mutants in gliomas and to pursue a systematic
comparison of minimally modified E1B-55 kDa mutant ver-
sus E1A mutant adenoviruses.
Taken together, our results show that Delta-24 and RA55
induce antiglioma effect in vitro and in vivo. Our data also
suggest that treatment with Delta-24 will be an option for
tumors that are resistant to the effect of E1B-55 kDa mutant
adenoviruses, especially for cancers that express wild-type
p53 protein. Finally, our data indicate that Delta-24 is a
powerful antiglioma agent; thus, preclinical data that will lead
to a clinical trial for testing the antiglioma effect of Delta-24
in patients with malignant glioma refractory to current forms
of treatment should be generated.
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Figure 6. Replication of Delta-24 and RA55 in intracranial U-87 MG human glioma xenografts. (A) Immunohistochemical analyses of hexon protein expression in a
section of a U-87 MG xenograft infected with Delta-24 from a mouse that died 20 days after implantation. The adenoviral structural hexon protein is detected in
cancer cells, indicating adenoviral replication in vivo (original magnification, 100). (B) Section of a U-87 MG xenograft treated with RA55 from a mouse that died
19 days after implantation stained for antihexon protein (original magnification, 100). Cells are nearly negative for the presence of viral hexon protein after
immunostaining and adenoviral replication is not evident.
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